You just read:

Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs

News provided by

Janssen EMEA

14 Jun, 2017, 11:25 ET